Synergistic Anti-tumor Effect of ChangTai Keli for Colon Cancer Patients

Colon Cancer Clinical Trial

Official title:

Synergistic Anti-tumor Effect of ChangTai Keli Based on Chemotherapy for Colon Cancer Patients：a Randomized, Parallel-group, Double-blind, Multicenter Clinical Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02510118
• Other study ID #: BL2014099-Y0103
• Secondary ID: Y0103
• Status: Recruiting
• Phase: Phase 2/Phase 3
• First received: July 12, 2015
• Last updated: July 30, 2015
• Start date: June 2015
• Est. completion date: June 2018

Study information

• Verified date: July 2015
• Source: Nanjing NingQi Medicine Science and Technology Co., Ltd.
• Contact: Yin Qingfeng, manager
• Phone: 0086-025-85632992
• Email: y_qingfeng[@]163.com
• Is FDA regulated: No
• Health authority: China:Jiangsu Department of Science and Technology
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to evaluate the synergistic anti-tumor effect of ChangTai Keli based on chemotherapy for colon cancer patients by a randomized, parallel-group, double-blind, multicenter clinical study.

Description:

Although many therapies exist and are being developed to relieve symptoms for colon cancer, there are few randomized controlled clinical trials to evaluate comprehensive Traditional Chinese medicine (TCM) interventions in colon cancer. The aim of this study is to evaluate the synergistic anti-tumor effect of ChangTai Keli based on chemotherapy for colon cancer patients. This is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the synergistic anti-tumor effect of TCM on colon cancer patients. Following a run-in period, approximately 360 subjects will be randomly assigned to conventional chemotherapy treatment group, ChangTai Keli and conventional chemotherapy treatment group for 26 weeks. After the 26 weeks treatment period, subjects in two treatments arms will follow-up 36 months.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 360
• Est. completion date: June 2018
• Est. primary completion date: June 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. collaboration from hospital oncology patients in hospital. Confirmed by pathology or cytology for colon cancer, ? A - ? period of patients with colon cancer line (or late postoperative palliative chemotherapy).

2. age > 18 years of age, and the 75 - year - old patient or less;

3. fitness score (ECOG PS) 2 minutes or less, expected lifetime > 6 months;

4. volunteered for the clinical research, and sign the informed consent.

Exclusion Criteria:

1. patients with other primary malignant tumors within 1 year;

2. intentional, severe liver and kidney disease patients with serious obstacle and function;

3. pregnancy or lactation women, mental disorders to cooperate to complete the healer;

4. is in other subjects or attended other drugs test interval < 3 months.

5. do not meet the inclusion criteria;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Colon Cancer

Intervention

Drug:
• mFOLFOX6
mFOLFOX6 regimen is a combination therapy of oxaliplatin (85 mg/m^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (2400 mg/m^2) via ambulatory pump administered for a period of 46 to 48 hours.
• XELOX
XELOX is a combination therapy of Oxaliplatin 130mg/ m^2 d1 Intravenous infusion, every 3 weeks. and Capecitabine 1000mg/m^2 bid, days 1-14, every 3 weeks
• Placebo ChangTai Keli
According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of dampness stasis type of spleen deficiency will be given placebo ChangTai Keli, twice daily for 26 weeks for lower dosage.
• ChangTai Keli
According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of dampness stasis type of spleen deficiency will be given placebo ChangTai Keli, twice daily for 26 weeks for lower dosage.

Locations

Country	Name	City	State
China	Jiege Huo	Nanjing	Jiangsu

Sponsors (2)

Lead Sponsor	Collaborator
Nanjing NingQi Medicine Science and Technology Co., Ltd.	Jiangsu Province Hospital of Traditional Chinese Medicine

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Adverse Event (AE)	Severity was graded using Common Terminology Criteria for Adverse Events (CTCAE) v3.0, with the exception of some dermatology/skin adverse events that were graded using CTCAE v3.0 with modifications. Fatal adverse events are classified as grade 5. Serious adverse events include any event that is fatal, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, a congenital anomaly/birth defect, or other significant medical hazard. Treatment-related AEs were those that the investigator considered a reasonable possibility that might have been caused by study drug.	The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date	Yes
Primary	Quality of life	Using QLQ-C30 (V3.0) to asses the impact of COPD on a person's life, and how this changes over time.	Change from Baseline in the QLQ-C30 (V3.0)at the week 2, 4, 6, 8, 10,13, 26 of the treatment phase, the week 13, 26, 39 and 52, 65, 78, 91, 104, 117, 130 of the followup phase.	No
Secondary	symptom	Using TCM scale to assess a patient's level of syptom. The symptom scale is a simple grading system that scored from 0, 2, 4, 6.	Change from Baseline in symptom score at the week 2, 4, 6, 8, 10,13, 26 of the treatment phase, the week 13, 26, 39 and 52, 65, 78, 91, 104, 117, 130 of the followup phase.	No
Secondary	Investigator-assessed Progression-Free Survival (PFS)	The time from the date of randomization until objective tumor progression or death due to any cause. Objective tumor progression was determined through radiological imaging and based on the requirements of the Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1)	3 years	No
Secondary	Progression-free Survival (PFS)		the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later)	No